These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

306 related articles for article (PubMed ID: 25412790)

  • 61. Three cases of facial erythema with dryness and pruritus in psoriasis patients during treatment with IL-17 inhibitors.
    Oiwa T; Honda T; Otsuka A; Kabashima K
    J Eur Acad Dermatol Venereol; 2018 Apr; 32(4):e122-e123. PubMed ID: 28983980
    [No Abstract]   [Full Text] [Related]  

  • 62. Association between the type and length of tumor necrosis factor inhibitor therapy and myocardial infarction risk in patients with psoriasis.
    Wu JJ; Poon KY; Bebchuk JD
    J Drugs Dermatol; 2013 Aug; 12(8):899-903. PubMed ID: 23986163
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Anti IL-17 flared psoriasis in a patient on secukinumab.
    Noell C; McQuade B; Gottlieb A; Rosmarin D
    Dermatol Ther; 2017 Jul; 30(4):. PubMed ID: 28547879
    [No Abstract]   [Full Text] [Related]  

  • 64. The relationship between tumour necrosis factor (TNF)-α promoter and IL12B/IL-23R genes polymorphisms and the efficacy of anti-TNF-α therapy in psoriasis: a case-control study.
    Gallo E; Cabaleiro T; Román M; Solano-López G; Abad-Santos F; García-Díez A; Daudén E
    Br J Dermatol; 2013 Oct; 169(4):819-29. PubMed ID: 23662788
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Survival rate of antitumour necrosis factor-α treatments for psoriasis in routine dermatological practice: a multicentre observational study.
    Esposito M; Gisondi P; Cassano N; Ferrucci G; Del Giglio M; Loconsole F; Giunta A; Vena GA; Chimenti S; Girolomoni G
    Br J Dermatol; 2013 Sep; 169(3):666-72. PubMed ID: 23647206
    [TBL] [Abstract][Full Text] [Related]  

  • 66. A follow-up study in 28 patients treated with infliximab for severe recalcitrant psoriasis: evidence for efficacy and high incidence of biological autoimmunity.
    Poulalhon N; Begon E; Lebbé C; Lioté F; Lahfa M; Bengoufa D; Morel P; Dubertret L; Bachelez H
    Br J Dermatol; 2007 Feb; 156(2):329-36. PubMed ID: 17223874
    [TBL] [Abstract][Full Text] [Related]  

  • 67. IL-17 targeted therapies for psoriasis.
    Chiricozzi A; Krueger JG
    Expert Opin Investig Drugs; 2013 Aug; 22(8):993-1005. PubMed ID: 23731078
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Serum sickness due to infliximab in a patient with psoriasis.
    Krishnan RS; Hsu S
    J Drugs Dermatol; 2004; 3(3):305-8. PubMed ID: 15176166
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Infliximab treatment for psoriasis in 120 patients on therapy for a minimum of one year: a review.
    Kamili QU; Miner A; Hapa A; Menter A
    J Drugs Dermatol; 2011 May; 10(5):539-44. PubMed ID: 21533302
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Psoriasis.
    Lebwohl M
    Lancet; 2003 Apr; 361(9364):1197-204. PubMed ID: 12686053
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Use of biologic agents in pediatric psoriasis.
    Marji JS; Marcus R; Moennich J; Mackay-Wiggan J
    J Drugs Dermatol; 2010 Aug; 9(8):975-86. PubMed ID: 20684148
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Treatment of recalcitrant pustular psoriasis with infliximab: effective reduction of chemokine expression.
    Benoit S; Toksoy A; Bröcker EB; Gillitzer R; Goebeler M
    Br J Dermatol; 2004 May; 150(5):1009-12. PubMed ID: 15149518
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Update on TNF Inhibitors in Dermatology.
    Sobell JM
    Semin Cutan Med Surg; 2016 Jun; 35(6 Suppl):S104-6. PubMed ID: 27537073
    [TBL] [Abstract][Full Text] [Related]  

  • 74. A scientific debate: key clinical questions in the management of psoriasis.
    Stingl G
    J Eur Acad Dermatol Venereol; 2012 Aug; 26 Suppl 5():1. PubMed ID: 22758910
    [No Abstract]   [Full Text] [Related]  

  • 75. A Review of Brodalumab, an IL-17 Receptor Antagonist, for Moderate-to-Severe Plaque Psoriasis.
    Tong Y; Peranteau AJ; Nawas Z; Tyring SK
    Skin Therapy Lett; 2017 Jan; 22(1):1-6. PubMed ID: 28122092
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Small molecules and antibodies for the treatment of psoriasis: a patent review (2010-2015).
    Chiricozzi A; Saraceno R; Novelli L; Fida M; Caso F; Scarpa R; Costa L; Perricone R; Romanelli M; Chimenti S; Chimenti MS
    Expert Opin Ther Pat; 2016 Jul; 26(7):757-66. PubMed ID: 27266423
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Pharmacogenetics and pharmacogenomics in psoriasis treatment: current challenges and future prospects.
    Sutherland A; Power RJ; Rahman P; O'Rielly DD
    Expert Opin Drug Metab Toxicol; 2016 Aug; 12(8):923-35. PubMed ID: 27266955
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Suicidal thoughts end Amgen's blockbuster aspirations for psoriasis drug.
    Schmidt C
    Nat Biotechnol; 2015 Sep; 33(9):894-5. PubMed ID: 26348946
    [No Abstract]   [Full Text] [Related]  

  • 79. Pathophysiological basis of systemic treatments in psoriasis.
    Volc S; Ghoreschi K
    J Dtsch Dermatol Ges; 2016 Jun; 14(6):557-72. PubMed ID: 27240060
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Effect of treating psoriasis on cardiovascular co-morbidities: focus on TNF inhibitors.
    Famenini S; Sako EY; Wu JJ
    Am J Clin Dermatol; 2014 Feb; 15(1):45-50. PubMed ID: 24281789
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.